Last reviewed · How we verify

NCT06239259

Validity and Reliability of Thai Version Clinical Questionnaire for Diagnosis of Carpal Tunnel Syndrome

Recruiting now Last updated 30 May 2025
What this trial tests

trial testing Questionare As described in Secondary Outcomes in Carpal Tunnel Syndrome in 80 participants. Currently enrolling.

Timeline
6 July 2023
Primary endpoint
31 December 2025
28 February 2026

Quick facts

Lead sponsorSiriraj Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment80
Start date6 July 2023
Primary completion31 December 2025
Estimated completion28 February 2026
Sites1 location across Thailand

Drugs / interventions tested

Conditions studied

Sponsor

Siriraj Hospital

Who can join

18 and older, any sex, with Carpal Tunnel Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Kamath and Stothard clinical questionnaire for diagnosing carpal tunnel syndrome (CTS) is a valid score for diagnosis of CTS. However it haven't been translated in to Thai version and the validity and accuracy of the Thai the Thai version have not been yet verified. The research team recognizes the importance and potential benefits of adapting this assessment for use within the Thai population.Therefore, we aim to conduct this research to translate the questionnaire from the original English to Thai and to assess its validity and reliability for diagnosing patients with Carpal Tunnel Syndrome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Carpal Tunnel Syndrome

Currently open trials in the same condition.

Other Siriraj Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06239259.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing